# Alzheimer's Disease Research Center

> **NIH NIH P30** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $3,029,312

## Abstract

Mount Sinai ADRC (Sano): OVERALL – Research Summary
Alzheimer's disease (AD) is a major health threat to the nation and the world causing great human pain and
economic loss. While some advances have been made in detection and raising awareness, finding treatments
has remained unsuccessful in spite of decades of research. To date, efforts have focused on defining the disease
by a narrow characterization of end-stage pathology, using restrictive samples and technologies that
systematically exclude the diversity of the disease. This approach has led to multiple failures, resulting in scant
progress on the therapeutic front. With this backdrop, the Mount Sinai Alzheimer's Disease Research Center
(MSADRC), with its history of success in therapeutic development dedicates itself anew to identify and develop
effective approaches to treating AD. Co-located in Manhattan on the Mount Sinai campus and in the Bronx at the
James J Peters Veterans Administration Medical Center, we bring the strength of two premiere institutions to the
mission of finding a treatment for AD. This application builds on these institutional strengths including systems-
based approaches to scientific inquiry, using the computational tools to mine big data and our established
expertise in recruiting diverse populations. We propose as our theme “Understanding disease heterogeneity to
optimize therapeutic approaches to treat and cure Alzheimer's disease” as it aligns our strengths with the
implementation areas and milestones of the National Alzheimer's Project Act (NAPA). We propose 7 cores
(Administrative, Clinical, Biomarker, Genetics, Neuropathology, Data, and Outreach) and a Research Education
Component, all of which have outstanding leadership reflecting newly recruited faculty as well investigators with
established histories at the MSADRC. Using the collaborative efforts of the Clinical and Outreach Core, enhanced
by novel methods of patient engagement through the electronic medical records at both locations, we propose to
expand and maintain a cohort of 450 diverse individuals, 40% of whom will be from under-represented minorities,
all receiving annual clinical evaluations, genetic analysis, and blood biomarker collection. The Genetics Core will
collect genetics data on all, generate GWAS, and will obtain plasma samples for established biomarkers and
proteomics on this diverse cohort. Our new Biomarker Core, supported by new philanthropy and existing research
efforts will obtain structural and functional imaging on all patients, and molecular phenotyping with CSF biomarkers
or molecular imaging on at least 50% of the cohort, capturing its full diversity. The Neuropathology Core,
expanding collection beyond brain to other relevant tissues and body fluids obtained at autopsy, will allow the
preparation of relevant brain regions for unbiased systematic sampling (stereology) and autopsy-derived
specimens for iPS, multiomics, microbiome, and exosome studies. The Data Core, enhanced by...

## Key facts

- **NIH application ID:** 9922011
- **Project number:** 1P30AG066514-01
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Mary Sano
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $3,029,312
- **Award type:** 1
- **Project period:** 2020-05-01 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9922011

## Citation

> US National Institutes of Health, RePORTER application 9922011, Alzheimer's Disease Research Center (1P30AG066514-01). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9922011. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*